Interleukin-13 receptor (IL-13R) a2 chain plays a key role in ligand binding and internalization. We have recently demonstrated that this cytokine receptor chain has unique characteristics in tumor biology: it inhibits tumorigenicity of breast and pancreatic cancer in animal models. In this study, we have exploited IL-13Ra2 chain and established a novel approach for pancreatic cancer therapy. For this, a plasmid encoding the IL-13Ra2 chain gene was mixed with liposomes and injected into subcutaneously or orthotopically xenografted human pancreatic tumors in immunodeficient mice, followed by systemic or local therapy by a recombinant IL-13 cytotoxin. Only tumors forced to express IL-13Ra2 chain acquired extreme susceptibility to the antitumor effect of IL-13 cytotoxin. There was a dominant infiltration of cells including macrophages and natural killer cells in the regressing tumors. Since macrophages were found to produce nitric oxide, IL-13Ra2-targeted cancer therapy involved not only a direct tumor cell killing by IL-13 cytotoxin but also activation of innate immune response at the tumor site. Therefore, this approach may be a new powerful tool for pancreatic cancer or other localized cancer therapy.
Introduction
Pancreatic cancer is one of the major causes of cancerrelated deaths in the United States, with 30 300 estimated new cases in 2002. 1 The estimated patient death by this cancer is 29 700 in a year. Although many approaches are employed to treat this malignancy including surgery and chemotherapy, median survival following diagnosis is only 6 months, which has not improved in the past 30 years. [2] [3] [4] [5] An effective new approach against this disease is desperately needed.
Interleukin-13 (IL-13) is a Th2 cell-derived pleiotropic immune regulatory cytokine. 6 It predominantly mediates biological activities in B cells and monocytes. IL-13 also mediates biological activities in tumor cells. [7] [8] [9] We have shown that the receptor for IL-13 (IL-13R) in tumor cells exists as two different types. [10] [11] [12] [13] [14] [15] Type I IL-13R consists of IL-13Ra2 (also known as IL-13Ra), IL-13Ra1 (also known as IL-13Ra 0 ), and IL-4Ra (also known as IL-4Rb) chains, while type II IL-13R consists of IL-13Ra1 and IL-4Ra chains. IL-13Ra1 chain [16] [17] [18] forms a heterodimer with IL4Ra chain and this complex mediates signal transduction through the JAK-STAT pathway. 14, 19 IL-13Ra2 chain 20, 21 does not seem to form a complex with any other known protein(s); it does not mediate signaling through STAT6 pathway but it is internalized after binding to ligand. 22, 23 IL-13Ra2 chain binds IL-13 with -50 times higher affinity than IL-13Ra1 chain. 20, 21 Although IL-13Ra2 chain is not observed to be present in immune cells, we have reported that this chain is expressed in many human tumor cells, for example, glioma, 9, 15 renal cell carcinoma, 12 ,24 AIDS Kaposi's sarcoma, 25 some ovarian cancer, 11, 24 head and neck cancer, 26, 27 and some normal fibroblasts. 24, 28 Thus, these tumors and fibroblasts express type I IL-13R. On the other hand, cancer cells derived from prostate, 29, 30 breast, 31 some head and neck, 26, 27 and some ovarian cancer 11, 24 express type II IL-13R.
To target IL-13R expressing cancer cells, we have developed a recombinant IL-13 fusion protein called IL-13 cytotoxin (IL13-PE, IL13-PE38, or IL13-PE38QQR). 26, 32 IL-13 cytotoxin is composed of IL-13 and a truncated form of Pseudomonas exotoxin, and has been shown to have a potent antitumor activity in vitro 25, 26, 29, 32, 33 and in vivo 25, 27, 30, 34 in many tumor models. Through extensive targeting studies, it has become apparent that there is a difference in sensitivity to IL-13 cytotoxin of many cancer types. The major reason for this difference is because of the type of IL-13R expressed on tumor cells. As IL-13Ra2 chain plays a major role in ligand binding and internalization, 22, 23 cells expressing type I IL-13R are much more sensitive to IL-13 cytotoxin when compared to cells expressing type II IL-13R. Based on these findings, we hypothesized if cancer cells were forced to express IL-13Ra2 chain, the cells may become highly sensitive to IL-13 cytotoxin. By in vitro transfection of this cytokine receptor chain into cancer cells, we have proven that IL-13Ra2 chain-positive cancer cells are rendered extremely sensitive to the cytotoxic effect of IL-13 cytotoxin. 27, 30, 35 Since pancreatic cancer is a localized disease with a high mortality rate, we are interested in developing a new therapeutic approach that can be directly translated into the clinic. In this study, we show that IL-13Ra2 chain-transfected pancreatic cancer cells acquire increased binding to IL-13 and sensitivity to the cytotoxic effect of IL-13 cytotoxin in vitro. Furthermore, in vivo direct gene transfer of IL-13Ra2 into tumors followed by systemic or intratumoral IL-13 cytotoxin therapy achieved dramatic regression of established tumors in subcutaneous or orthotopic models of pancreatic cancer.
Results
In vitro IL-13Ra2 gene transfer augmented IL-13 binding sites in pancreatic cancer cell lines
We determined IL-13R expression after gene transfer of the IL-13Ra2 chain in pancreatic cancer cell lines. As shown in Figure 1a , three pancreatic cancer cell lines (BxPC-3, CFPAC-1, and SU.86.86) did not express mRNA for IL-13Ra2 chain. When these cells were transiently transfected with IL-13Ra2 cDNA, IL-13Ra2 mRNA expression could be detected. Using BxPC-3 and CFPAC-1 cell lines, transfected with vector-only or IL13Ra2 chain cDNA, we also performed 125 I-IL-13 binding assays. Cells transfected with IL-13Ra2 cDNA showed a highly increased binding activity to radiolabeled IL-13 and this binding was displaced by excess of unlabeled IL-13, indicating specificity (Figure 1b) In vitro IL-13Ra2 gene transfer enhanced cytotoxicity of IL-13 cytotoxin to pancreatic cancer cell lines
We then assessed in vitro cytotoxic activity of IL-13 cytotoxin to pancreatic cancer cell lines transfected with vector only or IL-13Ra2 chain. As shown in Figure 2 , IL13-PE was not very cytotoxic to pancreatic cancer cell lines transfected with vector alone. On the other hand, these cells, when transfected with IL-13Ra2 cDNA, showed a highly increased sensitivity to IL13-PE in all the three cell lines. The IC 50 (the protein concentration required for the inhibition of protein synthesis by 50%) changed from 700 to 6.5 ng/ml in BxPC-3 cells, from 41000 to 170 ng/ml in CFPAC-1 cells, and from 41000 to 90 ng/ml in SU.86.86 cells, respectively. The cytototoxic activity of IL-13 cytotoxin to IL-13Ra2-transfected cells was blocked by an excess of IL-13 in all three cell lines, indicating that cytotoxicity mediated by this molecule is specific.
IL-2 cytotoxin is not cytotoxic to pancreatic cancer cells transfected with IL-13Ra2 chain
We also examined the cytotoxic activity of an irrelevant cytotoxin, IL2-PE40, 36 in BxPC-3 cells transfected with vector-only or IL-13Ra2 chain cDNA. PM-RCC naturally expressing IL-13Ra2 chain and CTLL-2 cells expressing IL-2R were used as positive controls to the IL-13 cytotoxin and IL-2 cytotoxin, respectively. As shown in Figure 3 , IL-2 cytotoxin was not cytotoxic to cells transfected with IL-13Ra2 chain cDNA (right panel; IC 50 41000 ng/ml), while IL-13 cytotoxin showed increased cytotoxicity to these cells compared to vector-only transfected cells (left panel; IC 50 ¼7.2 ng/ml). These data confirm that IL-13 cytotoxin-mediated cytotoxicity is IL-13Ra2 specific.
IL-13Ra2 chain expression in tumors after in vivo intratumoral vector administration
To examine gene expression of IL-13Ra2 chain in vivo, BxPC-3 tumors growing in the flank of nude mice were intratumorally injected with plasmid vector encoding IL13Ra2 cDNA or vector alone. Plasmids were mixed with liposomes for optimal in vivo gene transfer and injected on days 4 and 6 after tumor implantation. Tumors were subsequently resected at various time points after plasmid injections and subjected to RT-PCR and immunofluorescence microscopy analyses for IL-13Ra2 gene and protein expression. IL-13Ra2 chain mRNA In vivo IL-13Ra2 gene transfer in targeted pancreatic cancer therapy K Kawakami et al was found to be expressed continuously at high levels until day 17 in IL-13Ra2 cDNA-injected tumors (Figure 4a ). The level of expression was found to be decreased after day 20 of tumor implantation. These results were confirmed by immunofluorescence microscopy using monoclonal antibody to IL-13Ra2 chain (Figure 4b ). IL-13Ra2 chain protein expression was observed on day 8 (positive cells in the entire section were approximately 20-25%), which was decreased by day 20 (positive cells 5%). Whereas no positive cells were detected in vector-injected control tumors taken on days 8 and 20. These results indicate that the expression of IL-13Ra2 in the gene-transferred tumor site was maintained for up to 14 days after two injections of plasmid vector.
In vivo IL-13Ra2 gene transfer followed by IL-13 cytotoxin therapy efficiently causes the regression of subcutaneously xenografted pancreatic tumor growth in nude mice By in vivo liposomal-mediated plasmid injections, we were able to transfect pancreatic tumors with IL-13Ra2 cDNA. To target IL-13Ra2 expression on pancreatic tumor cell surfaces, we then evaluated the antitumor activity of IL-13 cytotoxin in subcutaneously xenografted BxPC-3 tumors in nude mice. First, we developed tumors in both right and left flanks of nude mice. Then, animals received either a vector injection (right flank) or an injection of IL-13Ra2 chain plasmid (left flank) intratumorally on days 4 and 6. The treatment was initiated on In vivo IL-13Ra2 gene transfer in targeted pancreatic cancer therapy K Kawakami et al Figure 5 Antitumor activity of IL-13 cytotoxin in subcutaneous xenograft models of pancreatic cancer after intratumoral administration of plasmid encoding the IL-13Ra2 chain. BxPC-3 (a) or CFPAC-1 (b) tumors were xenografted in both flanks of nude mice (n¼6). Tumors in the left flank were injected with IL-13Ra2 plasmid while tumors in the right flank were injected with vector only. Intratumoral injections were on days 4 and 6, followed by IL-13 cytotoxin administration either intraperitoneally (IP) or intratumorally (IT) on the days indicated by the arrows; b.i.d., twice a day and QD, once a day. ). One of six mice in the 250 mg/kg dose remained completely tumor-free in its left flanks until the end of the experiment on day 40.
We also employed another tumor model (CFPAC-1 tumor) for in vivo gene transfer of IL-13Ra2 chain followed by IL-13 cytotoxin treatment using a protocol similar to the BxPC-3 tumor model (Figure 5b ). CFPAC-1 tumors targeted with vector only (right flank) did not respond to the IL-13 cytotoxin treatment and grew in a linear manner similar to control tumors. For as long as we followed these animals (day 38), mean tumor size in control (excipient only) tumors treated intraperitoneally failed to exhibit any difference. The intratumoral treatment group showed a limited growth inhibition of tumors (Po0.01 between control and treatment groups). On the other hand, when tumors were injected with the IL-13Ra2 chain gene (left flank), they responded well to the antitumor effect of IL-13 cytotoxin. After intraperitoneal administration (25 Infiltrating macrophages producing nitric oxide (NO) were detected in IL-13 cytotoxin-treated pancreatic tumor site
To assess the mechanism of tumor regression by IL13Ra2 gene transfer followed by IL-13 cytotoxin therapy, subcutaneously xenografted pancreatic tumor-bearing In vivo IL-13Ra2 gene transfer in targeted pancreatic cancer therapy K Kawakami et al mice were treated following the above-mentioned protocol. BxPC-3 and CFPAC-1 tumors were resected on day 15 post-tumor implantation, and tumor sections were prepared. In BxPC-3 tumors treated with IL-13 cytotoxin (intraperitoneal 50 mg/kg dose) after vector injection, no tumor necrosis was detected (Figure 6a ). On the other hand, extensive tumor necrosis was observed after IL-13 cytotoxin treatment (intraperitoneal 50 mg/kg dose) in tumors that were injected with IL-13Ra2 cDNA ( Figure  6b) . Similarly, in CFPAC-1 tumors treated with IL-13 cytotoxin (intratumoral 250 mg/kg dose), no focal necrotic region was found after vector-only injection ( Figure  6c ), while clear central tumor necrosis was observed after IL-13Ra2 chain gene transfer (Figure 6d) . Interestingly, as shown in Figure 6e , many infiltrating cells were observed at the junctions between necrosis and remaining visible tumor region. To determine the identity of these cells, we performed immunohistochemical staining using unstained sections from the same paraffin block as shown in Figure 6d and e. From these experiments, we found that most cells stained moderately with F4/80 monoclonal antibody, indicating infiltration by macrophages (Figure 6f ). These cells were also positive for inducible nitric oxide synthase (iNOS; M19) (Figure 6g ). NK1.1 positive cells were also detected at the tumor site; however, staining intensity was weaker compared to F4/80 and M19 positive cells (data not shown). To determine whether iNOS positive cells were macrophages, we costained tumor sections with F4/80 (red) and M19 (green) antibodies and examined the sections by fluorescence microscopy. Both BxPC-3 tumors that received the IL-13Ra2 gene followed by 50 mg/kg dose of intraperitoneal IL-13 cytotoxin treatment (Figure 6h ) and CFPAC-1 tumors that received IL-13Ra2 gene followed by 250 mg/kg dose of intratumoral IL-13 cytotoxin treatment (Figure 6i) showed colocalization of macrophage and iNOS stains. Since iNOS is an inducible form of the enzyme producing NO, these data suggest that NO-producing macrophages may also participate in the tumor necrosis induced by IL-13Ra2 gene transfer followed by IL-13 cytotoxin administration.
Inhibition of NO causes reversal of IL-13 cytotoxin effect in CFPAC-1 cells cocultured with murine macrophages
We observed that NO was produced by macrophages infiltrating regressing pancreatic tumors as a result of IL13Ra2 gene transfer followed by IL-13 cytotoxin therapy in vivo. To investigate the role of macrophages and NO, we cocultured CFPAC-1 cells transfected with vector (control) or IL-13Ra2 chain with murine macrophages. Cocultured cells were incubated with IL-13 cytotoxin (100 ng/ml) for 48 h with or without NO inhibitor (N omonomethyl-L-arginine), and then viable CFPAC-1 cells were counted by trypan blue staining. As shown in Figure 7 , CFPAC-1 cells treated with murine macrophages were more sensitive to the cytotoxic effect of IL-13 cytotoxin. However, the combined effect of IL-13 cytotoxin and murine macrophages was higher in IL13Ra2-transfected CFPAC-1 cells compared to control. The presence of NO inhibitor reversed this cytotoxicity and the number of viable cells in both control and IL13Ra2-transfected CFPAC-1 tumor cells returned to baseline comparable to only NO inhibitor-treated group. These results suggest that NO produced by murine macrophages play some role in the killing of IL-13Ra2-positive pancreatic cancer cells by IL-13 cytotoxin.
Assessment of organ toxicity after IL-13 cytotoxin administration
To examine whether intratumorally administrated IL13Ra2 plasmid migrated to distant vital organs resulting in IL-13 cytotoxin-mediated organ toxicity, we harvested (Figure 8) . We also performed immunohistochemical staining using monoclonal antibody to IL13Ra2 chain. However, no detectable protein expression was observed in any organs examined except for IL13Ra2 chain gene-transferred tumor (data not shown). Additionally, we collected major organs (heart, liver, lung, kidney, and spleen) from CFPAC-1 xenografted mice that had received IL-13Ra2 intratumoral injections followed by IL13-PE treatment either by intraperitoneal (50 mg/kg dose) or intratumoral (250 mg/kg dose) routes, on day 15 after tumor implantation. Organ toxicities were assessed by histological examination. A slight tubular necrosis was observed in kidney from a mouse treated with intratumoral IL-13 cytotoxin. However, all the other organs were free from any evidence of pathological changes (data not shown). All the treated mice tolerated intraperitoneal and intratumoral doses well without any visible toxicity.
In vivo IL-13Ra2 gene transfer followed by systemic IL-13 cytotoxin therapy arrested aggressive growth of pancreatic tumors orthotopically implanted in nude mice
To examine the effectiveness of a combined therapeutic approach on the orthotopic pancreatic cancer model, we surgically implanted tumor pieces in the pancreas of immunodeficient mice. This mode of tumor implantation produced 100% uptake of tumors and all the animals showed aggressive tumor growth invading pancreas and spleen.
37 Implanted CFPAC-1 tumors then received either IL-13Ra2 cDNA or vector at the time of tumor implantation followed by another injection 2 days after the tumor implantation. Animals were then injected with excipient alone (control) or IL-13 cytotoxin (50 mg/kg, twice a day Â 5 days from days 4 to 8 after the implantation) intraperitoneally. Tumors in animals that received IL-13Ra2 followed by IL-13 cytotoxin injection remained neither visible nor palpable for the duration of the experiment (day 28). In contrast, animals in other groups developed tumors, which were visible and palpable transcutaneously at 2-3 weeks. Animals were killed on day 28 to assess tumor weight and histology. As shown in Figure 9a and b, mean tumor weight from mice receiving IL-13Ra2 cDNA followed by IL-13 cytotoxin treatment was 0.36 g, which was significantly smaller than tumors in other groups (Po0.001 versus tumors in vector-only injections followed by excipient treatment group (1.23 g); Po0.003 versus tumors in vector-only injections followed by IL-13 cytotoxin treatment group (0.98 g)). These results suggest that a therapeutic approach that combines in vivo IL-13Ra2 chain gene transfer and systemic treatment by IL-13 cytotoxin is effective in reducing tumor size.
By histological examination, we found no detectable tumor cells in the pancreas or spleen of one mouse that received IL-13Ra2 cDNA and IL-13 cytotoxin (Figure 9c ). Tumors from three other mice in the IL-13Ra2 cDNA and IL-13 cytotoxin-treated group showed a large area of central necrosis (not shown). On the other hand, Figure 9 Growth of pancreatic tumors orthotopically xenografted in nude mice was inhibited by IL-13Ra2 gene transfer followed by systemic IL-13 cytotoxin treatment. Animals surgically implanted with CFPAC-1 orthotopic tumors were injected twice with either vector-only or IL13Ra2 encoding plasmid, followed by excipient or IL-13 cytotoxin treatment (intraperitoneally, 50 mg/kg twice a day for 5 days). Tumors were collected at day 28 after tumor implantation (a) and mean weight was calculated (b). Histological examination shows CFPAC-1 tumors invading pancreas and spleen, while no remaining tumor is shown in one sample from IL-13Ra2 gene transfer and IL-13 cytotoxin received mice (c). Tu, tumor; Pa, pancreas; Sp, spleen. In vivo IL-13Ra2 gene transfer in targeted pancreatic cancer therapy K Kawakami et al profound infiltration of tumor cells invading pancreas and spleen was observed in mice from the other three treatment groups (Figure 9c ). In addition, we did not observe any toxicity in vital organs (eg, heart, liver, lung, kidney, and spleen) of animals that received the IL-13Ra2 gene followed by IL-13 cytotoxin administration when tissues were collected on day 11 and assessed by histological examination (data not shown).
We also assessed the survival of mice bearing BxPC-3 orthotopically xenografted tumors receiving either vector only followed by excipient injections, or IL-13Ra2 cDNA followed by IL13-PE injections. The treatment schedule was similar to the CFPAC-1 orthotopic tumor-bearing animals. In the control group, animals developed tumors that were visible and palpable transcutaneously at 3-4 weeks. Animals began dying starting 70 days after tumor implantation and the median survival was 79.7 days (n¼7). In contrast, animals that received IL-13Ra2 cDNA intratumorally followed by IL-13 cytotoxin treatment showed growth arrest resulting in enhancement of median survival (102.7 days, n¼7) compared to control mice.
Discussion
In this study, we demonstrate that pancreatic tumors can be engineered to express IL-13Ra2 chain by in vivo plasmid-mediated gene transfer, and subsequently administration of IL-13 cytotoxin can mediate a potent antitumor activity in animal models of human pancreatic cancer, implanted either subcutaneously or orthotopically. Pancreatic tumor cells did not naturally express IL-13Ra2 chain, and consequently these cells did not bind radiolabeled IL-13 and did not show a cytotoxic activity when exposed to IL-13 cytotoxin. However, when IL-13Ra2 chain was transfected into the tumor cells, they bound IL-13 at high levels and IL-13 cytotoxin mediated remarkable cytotoxic activity in vitro. This cytotoxicity was specific as an irrelevant toxin (IL2-PE40) did not mediate cytotoxicity upon IL-13Ra2 gene transfer.
To extend our in vitro results to the in vivo model, we established human pancreatic tumors subcutaneously in immunodeficient mice. These tumors were then injected with IL-13Ra2 cDNA mixed with liposomes to study: (i) whether IL-13Ra2 chain can be expressed in vivo in tumors, (ii) the time frame of gene expression, and (iii) whether IL-13 cytotoxin will mediate antitumor activity as seen in cell cultures. Our data demonstrate that IL13Ra2 can be highly expressed in vivo by intratumoral administration of IL-13Ra2 plasmid. High levels of IL13Ra2 mRNA expression was evident until day 14 of tumor implantation followed by a decline in gene expression until day 23 when IL-13Ra2 mRNA was barely detectable. IL-13Ra2 protein expression was also confirmed by immunohistochemistry in tumor tissue sections obtained from IL-13Ra2 cDNA-injected tumors at various time points. The protein expression appeared to be optimal at day 8 of tumor implantation and this expression level decreased by day 20. When IL-13Ra2 cDNA-injected tumor-bearing mice were treated with IL-13 cytotoxin by either intraperitoneal or intratumoral routes, profound antitumor activity was observed. Statistically significant tumor regression was observed in IL-13Ra2-injected tumors compared to control animals. Intratumoral administration of IL-13 cytotoxin mediated better antitumor activity, most likely because of a high local concentration of drug, complete regression of tumors was observed in some animals. Vector-injected tumors showed minimum antitumor activity when mice were treated intratumorally by IL-13 cytotoxin. As pancreatic tumor cells express IL-13Ra1 and IL-4Ra chains forming a type II IL-13R complex, weak antitumor activity may be mediated through this receptor system. 14, [16] [17] [18] In contrast, the predominant antitumor activity in IL-13Ra2 gene transfected tumors may be mediated by type I IL-13R that have incorporated the IL13Ra2 chain.
Subcutaneous tumor regression induced by IL-13Ra2 chain gene expression followed by IL-13 cytotoxin administration was examined by H&E staining and immunohistochemistry. Extensive necrosis was observed in tumors injected with IL-13Ra2 cDNA plasmid followed by IL-13 cytotoxin injections by intraperitoneal or intratumoral routes. Interestingly, infiltration of inflammatory cells was observed at the junction of the necrotic lesions and the remaining viable tumor. These cells were macrophages and some NK cells suggesting that the innate immune system was induced by IL-13 cytotoxin-mediated tumor necrosis. The infiltrating macrophages were strongly positive for iNOS indicating that these cells may produce NO in vivo. As only 20-25% of the pancreatic tumor cells were transduced with IL13Ra2 cDNA, our data suggest that NO may play a significant bystander role in the regression of established tumors.
The role of macrophages and NO in tumor regression was confirmed by in vitro experiments ( Figure 7) ; however, the involvement of other possible mechanisms remained to be explored. It is possible that IL-13Ra2 gene was transduced in intratumoral endothelial cells and stromal cells, which then became susceptible to the cytotoxic effect of IL-13 cytotoxin resulting in tumor regression. Alternatively, it is possible that activated host cells mediated antiangiogenic activity resulting in complete tumor regression. On the other hand, it might be more difficult to obtain complete tumor regression in immunocompetent hosts as host-negative regulatory influences mediated by tumor factors might dampen such macrophage reactivity. Finally, a complicated cascade of events may be involved for recruiting NOproducing macrophages for tumor regression. Further studies will examine these possibilities.
The antitumor activity of IL-13 cytotoxin following IL13Ra2 cDNA injection into tumors was further confirmed in the orthotopic pancreatic tumor model. IL-13 cytotoxin-induced reduction or disappearance of established pancreatic tumors in IL-13Ra2 cDNA-injected mice, but not in vector-only or IL-13 cytotoxin-only treated mice. The weight of tumors was significantly reduced in IL-13Ra2 cDNA-injected tumors compared to vector-only injected tumors. In addition, the median survival of mice injected with IL-13Ra2 cDNA followed by IL-13 cytotoxin administration was slightly longer compared to control animals. The treatment of IL-13Ra2 cDNA-injected orthotopic tumor by IL-13 cytotoxin therapy caused complete disappearance of tumor in histological sections or showed extensive necrosis of tumors. These data demonstrate that IL-13 cytotoxin has
In vivo IL-13Ra2 gene transfer in targeted pancreatic cancer therapy K Kawakami et al profound antitumor activity when orthotopic pancreatic tumors were preinjected with IL-13Ra2 cDNA.
It is important to note that IL-13Ra2 cDNA and gene expression was localized only in the injected subcutaneous tumors. mRNA and protein for IL-13Ra2 chain were undetected in various vital organs including peripheral blood cells. In addition, all the vital organs obtained from mice that received intratumoral IL-13Ra2 cDNA followed by IL-13 cytotoxin injection did not show any severe histological changes. These results suggest that this mode of plasmid injection either in subcutaneous or orthotopic tumors did not allow migration of sufficient plasmid for the detection of mRNA or protein expression in vital organs. It is possible that plasmid vector migrated to vital organs but was not detected as tissues were harvested 3 days after plasmid injection followed by IL-13 cytotoxin administration (on day 15). Testing of vital organs at earlier time points may have been positive. Nevertheless, this hypothetical migration did not lead to tissue damage by IL-13 cytotoxin administration.
IL-13Ra2 chain has unique characteristics in tumor biology. We have demonstrated that this chain can bind IL-13 at higher affinity and internalize after binding to ligand but it does not mediate signal transduction through the STAT6 pathway. 22, 23 Terabe et al demonstrated that the soluble form of IL-13Ra2 chain can sequester IL-13, shifting the immune environment from Th2 to Th1 in the presence of tumor, resulting in resistance to the 15-12RM cell derived-tumor recurrence. 38 They hypothesized that IL-13 produced by natural killer T (NKT) cells utilizes the STAT6 pathway, which is necessary for the downregulation of tumor immunosurveillance. We have recently demonstrated that breast (MDA-MB-231) and pancreatic (PANC-1) cancer cells stably transfected with IL-13Ra2 chain lose their tumorigenicity in immunodeficient mice. 39 Infiltrated neutrophils that produce IL-13 in IL-13Ra2 overexpressing tumors, and IL-8 released by tumor cells in response to IL-13 seemed to play a complex role in the tumor inhibition mechanism. However, in the present study, injection of IL-13Ra2 plasmid in established tumors did not modulate tumor growth. These studies suggest that IL-13Ra2 chain plays a major role in tumorigenesis and tumor immunosurveillance, but this effect depends on the timing of IL-13Ra2 administration.
Previous studies have demonstrated that IL-13 cytotoxin mediates potent antitumor activity against IL-13R expressing tumors in vivo through necrosis as well as apoptotic tumor cell death. 25, 27, 30, 34, 40, 41 Therefore, our approach that utilizes gene transfer of IL-13Ra2 chain is an ideal way to maximize the effect of IL-13 cytotoxin for cancer therapy.
Our studies can be directly applied to clinical situations. Technically, it is feasible to inject IL-13Ra2 plasmid into pancreatic tumors safely under the guidance of an ultrasound device, followed by systemic IL-13 cytotoxin administration. Alternatively, novel delivery mechanisms may be developed in which high doses of IL-13 cytotoxin may be given by ultrasound-guided catheter delivery for intratumoral administration followed by low-dose systemic administration.
So far, few agents have been shown to cause regression of advanced pancreatic cancer in humans. [2] [3] [4] [5] There are several reports that have demonstrated the effectiveness of some targeted strategies involving monoclonal antibodies or immunotoxins to treat pancreatic cancer. 3, 42 These approaches were limited because expression of the target antigens was insufficient to deliver targeting agents in sufficient quantity to eliminate all cancer cells. 43 Our approach overcomes this problem as gene transfer of only one chain of a cytokine receptor system binds significant molecules of cytotoxin to cause profound antitumor activity. Unexpectedly, our approach not only sensitized pancreatic cancer cells to the IL-13 cytotoxin, it also recruited innate 'effector cells' that help mediate profound antitumor activity. Thus, a combination approach involving IL-13Ra2 gene transfer and IL-13 cytotoxin therapy may provide a robust approach for pancreatic cancer therapy.
Materials and methods

Recombinant cytokine, cytotoxin, and cell lines
Recombinant human IL-13 and IL-13 cytotoxin (IL13-PE38QQR) were produced and purified to near homogeneity in our laboratory. 26, 44 Human pancreatic cancer cell lines (BxPC-3, CFPAC-1, and SU.86.86) were purchased from the American Type Culture Collection. Cells were cultured in RPMI 1640 (BxPC-3 and SU.86.86) or Iscove's modified Dulbecco's medium (CFPAC-1) containing 10% fetal bovine serum (Biowhittaker Inc., Walkersville, MD, USA), 1 mM HEPES, 1 mM L-glutamine, 100 mg/ml penicillin, and 100 mg/ml streptomycin (Biowhittaker).
In vitro transfection
cDNA encoding human IL-13Ra2 chain 9, 20 was cloned into the VR1020 mammalian expression vector (a kind gift from Vical Inc., San Diego, CA, USA) using Pst I and Bgl II sites, and the sequences of the flanking regions of the junctions were verified by direct sequencing. Gene expression of IL-13Ra2 cDNA in the VR1020 vector is driven by the CMV promotor. 45 Plasmid DNA (12 mg/ 100-mm culture dish) was transfected into semiconfluent cells using GenePORTER transfection reagent (Gene Therapy Systems, San Diego, CA, USA) according to the manufacturer's instructions. Briefly, cells (2 Â 10 6 / 100-mm dish) were incubated with the DNA-GenePOR-TER mixture for 5 h in DMEM followed by 20 h incubation in fresh DMEM containing 20% FBS and then an additional 24 h in medium with 10% FBS.
RT-PCR
To detect the mRNA expression in cells or tumors developed in mice, total RNA was isolated using TRIZOL reagent (Life Technologies, Inc., Grand Island, NY, USA), and then RT-PCR was performed using specific primers as described. 24 
Radioreceptor binding assays
Recombinant human IL-13 was labeled with 125 I (Amersham Pharmacia Biotech, Arlington Heights, IL, USA) using IODO-GEN reagent (Pierce Chemical Co., Rockford, IL, USA) as previously described. 46 The specific activity of the radiolabeled IL-13 was estimated to be 15. I-IL-13 with or without unlabeled IL-13 (40 nM) at 41C for 2 h. Cell-bound 125 I-IL-13 was separated from unbound by centrifugation through a phthalate oil gradient and radioactivity was determined with a g counter (Wallac, Gaithersburg, MD, USA).
Protein synthesis inhibition assay
The cytotoxic activity of IL-13 cytotoxin was tested as previously described. 47 Typically, 10 4 cells were cultured in leucine-free medium with or without various concentrations of IL13-PE38QQR for 20-22 h at 371C. Then 1 mCi of [ . 48 In subcutaneously xenografted tumors, injections (total volume 50 ml/injection) were performed at days 4 and 6 after tumor implantation. In orthotopically xenografted tumors, the first intratumoral injection was made at the same time as the surgical tumor implantation, and the second similar injection was made 2 days after the first injection under ketamine and xylazine anesthesia. For antitumor activity, mice were injected with IL13-PE38QQR or excipient either intraperitoneally (500 ml/mouse) or intratumorally (30 ml/tumor) from days 8 to 12.
Immunohistochemistry
Immunohistochemistry was performed using the Vector ABC peroxidase kit (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's instructions. Subcutaneous tumor samples were harvested 3 days after the IL13-PE38QQR treatment (day 15) and fixed with 10% formalin or snap frozen with OCT compound.
Paraffin-embedded sections were deparaffinized by xylene treatment and washed with alcohol (100 to 50%) and PBS. Slides were incubated with antibodies against murine macrophage (F4/80; Caltag Laboratories, Burlingame, CA, USA), NK cells (NK1.1; Caltag Laboratories), or iNOS (M19; Santa Cruz Biotechnology, Santa Cruz, CA, USA) (0.4-1 mg/ml) or isotype control for 18 h at 41C. Slides were then developed using DAB substrate biotinylated peroxidase reagent (Vector Laboratories) and counterstained with hematoxylin (Sigma-Aldrich, Inc.). Immunohistochemical assays were performed 2-3 times independently with similar results and slides were assessed by two independent investigators.
For immunofluorescent assays, frozen sections were stained with antihuman monoclonal antibody for IL13Ra2 (Diaclone, Besancon, France) or costained with antibodies for macrophages and iNOS. Slides were fixed in acetone at À201C for 5 min and air-dried. Nonspecific binding was blocked by treatment with 10% serum for 1 h followed by incubation with antibodies or isotype control. Sections were subsequently incubated for 1 h with secondary antibodies that had either tetramethylrhodamine isothiocyanate or FITC tags. After three washes with PBS, slides were dried and layered with Vectashield antifluorescence fading mounting medium (Vector Laboratories) and a covership. The slides were viewed in an Olympus IX70 fluorescence microscope using appropriate filters (Olympus Optical Co., Tokyo, Japan). Images were compiled from sets of three consecutive single optical sections using SPOT INSIGHT V 3.2 software (Diagnostic Instruments, Sterling Heights, MI, USA).
Murine macrophages preparation and NO inhibition assay
Athymic nude mice were injected i.p. with thioglycolate (40 mg/1 ml PBS/mouse). Five days after injection, mice were killed and peritoneal exudate cells were collected by washing peritoneum with cold PBS. Cells were incubated with ACK lysis buffer (Biowhittaker Inc.), washed with cold PBS, and 1 Â 10 6 cells were seeded in six-well plates with DMEM.
For NO inhibition experiments, 0.5 mM N o -monomethyl-L-arginine (MLA; Sigma-Aldrich, Inc.) was added to pancreatic cancer cells cocultured with murine macrophages.
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Statistical analysis
Tumor size was calculated by multiplying length and width of the tumor on a given day. The statistical significance of tumor regression was calculated by Student's t-test. All statistical tests were two sided.
